ResearcherHuazhong University of Science and TechnologyNo recent work listed

Andong Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-8012-7352; OpenAlex author ID A5103035615. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper

Papers 2

Blockade of DDR1/PYK2/ERK signaling suggesting SH2 superbinder as a novel autophagy inhibitor for pancreatic cancer. Last author DOI 10.1038/s41419-023-06344-4 ↗
Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.337 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hui Xu · 2 shared papers, 2021–2023 · strength 0.33
- Paper Blockade of DDR1/PYK2/ERK signaling suggesting SH2 superbinder as a novel autophagy inhibitor for pancreatic cancer. DOI 10.1038/s41419-023-06344-4 ↗
- Paper Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. DOI 10.1002/ctm2.337 ↗
Xuan Cao · 2 shared papers, 2021–2023 · strength 0.33
- Paper Blockade of DDR1/PYK2/ERK signaling suggesting SH2 superbinder as a novel autophagy inhibitor for pancreatic cancer. DOI 10.1038/s41419-023-06344-4 ↗
- Paper Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. DOI 10.1002/ctm2.337 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.